SLC12A2 and stroke disorder: One such inhibitor is the specific NKCC1 inhibitor, Bumetanide that shows promise as a potential therapy for AD (Taubes et al., 2021; Graber-Naidich et al., 2023a; Graber-Naidich et al., 2023b; Boyarko et al., 2023) and for modifying post-stroke brain changes (O'Donnell et al., 2004).